clinical trial · NCT07073638
Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis
Thirty Respiratory Limited·phase2·recruiting·n = 24
Pulmonary TuberculosesRESP30TBHRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
brief summary
A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
started
Oct 13, 2025
primary completion
Sep 15, 2026
completion
Nov 15, 2026
last updated
Jan 12, 2026
detailed description
This is a single-centre, open-label, single arm, clinical trial in two sequential stages, with no stratification. 12 patients will be enrolled in Stage 1, and a further 12 patients will be enrolled in Stage 2 (total of 24 patients in the trial).
official title
A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults With Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol